Podcasts about prostvac

Synopsis: In this episode of BioTech 2050, Robert Ang, CEO of Vor Bio, shares insights on the current state of cancer therapies and next-gen modalities. He discusses Vor Bio's work on shielded stem cell transplants and CAR T-cell therapies targeting hematologic malignancies like AML and MDS. Robert also talks about his experience serving on boards and emphasizes the importance of core values in shaping organizational culture. He highlights his approach to hiring, focusing on finding individuals who are passionate about making an impact over titles. Overall, the discussion provides valuable insights into the evolving landscape of cancer treatment. Biography: Robert Ang, MBBS, MBA brings experience as a senior biotech executive and is formerly a physician, venture capitalist, and strategy consultant. Prior to Vor Bio, Robert was Chief Business Officer at Neon Therapeutics, serving as part of the early team that established the company prior to its Series A investment through IPO. Before Neon, he served as Senior Vice President of Business Development at Bavarian Nordic, where he was primarily responsible for conducting a $975 million transaction with Bristol-Myers Squibb for PROSTVAC, a Phase 3 immuno-oncology asset, and served as Head of Business Development and Medical Affairs for Cadence Pharmaceuticals. Robert also worked at Frazier Healthcare Ventures, a leading life sciences venture capital firm, where he was involved in several pharmaceutical and biotechnology investments including Cadence Pharmaceuticals (purchased by Mallinckrodt), Incline Therapeutics (purchased by The Medicines Company), Alnara Pharmaceuticals (purchased by Eli Lilly), and Collegium Pharmaceuticals. Robert also has strategy consulting experience at the Boston Consulting Group and has general surgical training. He holds an MBBS (Doctor of Medicine) from the University of Western Australia and an MBA with honors from Columbia Business School. Robert serves as the Board Chair of Enara Bio, a UK-based biotechnology company focused on non-classical HLA targets for immuno-oncology approaches. He is also a member of the Executive Committee of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies.

Dr. Daniel Goldstein reviews data by Drs. Gulley & colleagues on PROSTVAC vaccine in metastatic prostate cancer & discusses the implications of trials that fail in phase III despite looking extremely favorable in phase II studies.

Hvad så nu din aktiebav(a)(r)ian? I det 25. afsnit af #pengemedper får jeg igen besøg af chefen for IR hos Bavarian Nordic, Rolf Sass Sørensen. Anledningen er den noget kedelige, at et ekspertpanel for et par uger siden vurderede, at data fra Prostvac ikke var stærke nok til at retfærdiggøre den videre færd i fase 3 med en monobehandling mod Prostatakræft. Aktien blev på dagen skåret midt over i 2 omtrent lige små halvdele. Prostvac – attraktiv i kombinationsbehandling? Vi har hørt meget om Prostvac og konsekvenserne af, at det ikke bliver muligt at markedsføre den, som en monobehandling. Selv om dataene var overraskende og skuffende, har monobehandlingen ikke været den som Bavarian Nordic selv har lagt mest vægt på. Hør mere om hvorfor. Hør derudover mere om: • Hvad er status? • Har de skuffende resultater rokket ved jeres tillid til andre projekter? • Har Prostvac betydet noget for jeres partnerrelationer? • Tidsmæssig opdatering: Hvornår kommer der nyt om Prostvac data og næste skridt for CV-301 og RSV? • Status på det finansielle beredskab? • Feed back på kapitalmarkedsdag i New York

I afsnit 13 af #pengemedper skal det dreje sig om biotek og en af de private aktiefavoritter; Dagens gæst kommer fra et selskab, som bl.a. laver vacciner og håber at have fundet den bedste behandling mod prostatakræft. Men Bavarian Nordic er meget andet end blot Prostvac. I studiet er jeg sammen med chefen for Investor Relations Rolf Sass Sørensen. Du kan bl.a. høre om • Hvorfor Bavarian er andet og mere end kun koppevacciner og Prostvac • Hvor Bavarian Nordic ser op til Genmab • Hvorfor der er gode synergier mellem de enkelte aktiviteter i Bavarian Nordic • Og meget andet Sidst men ikke mindst kan du høre, hvad Rolf Sass Sørensens syn og anbefaling var på Genmab, da han tidligere var aktieanalytiker.

Dr. James Gulley, National Cancer Institute, discusses immunotherapies for genitourinary cancers, including recent trial results. He also addresses early data which may indicate that using immunotherapy sooner may benefit patients.

Dr. James Gulley, National Cancer Institute, discusses immunotherapies for genitourinary cancers, including recent trial results. He also addresses early data which may indicate that using immunotherapy sooner may benefit patients.

Dr. James Gulley, National Cancer Institute, discusses immunotherapies for genitourinary cancers, including recent trial results. He also addresses early data which may indicate that using immunotherapy sooner may benefit patients.